碳离子再程放疗用于碳离子放疗后复发头颈部恶性肿瘤的可行性
本研究回顾性分析了48例碳离子放疗后复发头颈部恶性肿瘤患者接受碳离子再程放疗的资料,中位再程放疗剂量为54.0 Gy(RBE),中位随访27.1个月。5例(10.4%)发生3级急性毒性,18例(37.5%)发生≥3级晚期毒性,包括1例5级中枢神经系统坏死。2年局部控制率、局部区域控制率、无进展生存率和总生存率分别为40.5%、33.5%、29.4%和59.6%。作者认为碳离子再程放疗可能是毒性可接受的合理治疗选择。
要点
- 48例碳离子放疗后复发头颈部恶性肿瘤患者接受碳离子再程放疗,中位剂量54.0 Gy(RBE)。
- 18例(37.5%)发生≥3级晚期毒性,包括1例5级中枢神经系统坏死。
- 2年局部控制率40.5%,总生存率59.6%。
核心结论
- 作者认为,对于碳离子放疗后复发的头颈部恶性肿瘤患者,碳离子再程放疗可能是毒性可接受的合理治疗选择。
研究设计与样本
- 回顾性分析2007年至2016年在本机构接受碳离子再程放疗的48例碳离子放疗后复发头颈部恶性肿瘤患者的资料。
- 再程放疗时肿瘤复发部位包括鼻腔鼻窦18例(37.5%)、鼻腔9例(18.8%)、鼻咽4例(8.3%)、眶3例(6.3%)、海绵窦3例(6.3%)及其他部位11例(22.9%)。
- 初次碳离子放疗中位剂量为57.6 Gy(RBE),再程放疗中位剂量为54.0 Gy(RBE)。
- 所有患者均未接受同步化疗。
主要发现
- 再程放疗后中位随访27.1个月。
- 5例(10.4%)发生3级急性毒性,18例(37.5%)发生≥3级晚期毒性,包括1例5级中枢神经系统坏死。
- 2年局部控制率为40.5%,局部区域控制率为33.5%,无进展生存率为29.4%,总生存率为59.6%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Locoregional recurrence after carbon-ion radiotherapy (CIRT) for primary head and neck malignancies, such as malignant mucosal melanoma, adenoid cystic carcinoma, and sarcoma, occurs occasionally. However, the treatment options are limited. We report on the toxicity and efficacy of re-irradiation using carbon ions for recurrent head and neck malignancies after CIRT. MATERIALS AND METHODS: Data of 48 patients with recurrent head and neck malignancies treated with re-irradiation with CIRT at our institution (2007-2016) were retrospectively analyzed. Twenty-one patients (43.8%) had malignant mucosal melanoma, 17 (35.4%) had adenoid cystic carcinoma, six (12.5%) had bone and soft tissue sarcomas, and four patients (8.3%) had other disease types. Tumor recurrences at re-irradiation were located in the paranasal cavity (n = 18, 37.5%), nasal cavity (n = 9, 18.8%), nasopharynx (n = 4, 8.3%), orbit (n = 3, 6.3%), cavernous sinus (n = 3, 6.3%), and at other sites (n = 11, 22.9%). The median dose of initial CIRT and that at re-irradiation were 57.6 Gy and 54.0 Gy (relative biological effectiveness [RBE]), respectively. None of the patients received concurrent chemotherapy. RESULTS: The median follow-up period after re-irradiation was 27.1 months. Five patients (10.4%) developed Grade 3 acute toxicities and 18 (37.5%) developed Grade ≥3 late toxicities, including Grade 5 central nervous system necrosis in one patient. The 2-year local control, locoregional control, progression-free survival, and overall survival rates were 40.5, 33.5%, 29.4%, and 59.6%, respectively. CONCLUSION: Re-irradiation using carbon ions may be a reasonable treatment option with tolerable toxicity for patients with recurrent head and neck malignancies after CIRT.
引用
- Hayashi K, Koto M, Ikawa H, et al. Feasibility of Re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. Radiother Oncol. 2019. PMID: 31015117. doi:10.1016/j.radonc.2019.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。